We are live on
!
Find out more
FGP
Foyston, Gordon, & Payne Portfolio holdings
AUM
$468M
1-Year Est. Return
6.67%
This Fund
S&P 500
This Quarter
Est. Return
+5.05%
1 Year Est. Return
+6.67%
3 Year Est. Return
+57.25%
5 Year Est. Return
+83.16%
10 Year Est. Return
+253.32%
AUM
$787M
AUM Growth
-$24.3M
(-3%)
Cap. Flow
-$58.4M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
86
New
1
Increased
12
Reduced
49
Closed
5
Avg Time Held
3.5
quarters
Top 10 Avg Time Held
2.3
quarters
Top 20 Avg Time Held
3.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$16M |
| 2 |
Medtronic
MDT
|
+$6.22M |
| 3 |
Knowles
KN
|
+$4.68M |
| 4 |
Baxter International
BAX
|
+$4.2M |
| 5 |
Shinhan Financial Group
SHG
|
+$734K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$13.5M |
| 2 |
Ryder
R
|
+$5.64M |
| 3 |
ICICI Bank
IBN
|
+$4.68M |
| 4 |
Jabil
JBL
|
+$4.55M |
| 5 |
BHI
Baker Hughes
BHI
|
+$4.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.58% |
| 2 | Technology | 15.83% |
| 3 | Financials | 15.07% |
| 4 | Energy | 11.76% |
| 5 | Consumer Staples | 9.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Teva Pharmaceutical Industries Limited
TEVA
$48.8B
| $35.4M | 4.49% |
674,888
+313,877
| +87% | +$16M |
2013 Q3
3 quarters
|
|
2
Conagra Brands
CAG
$6.55B
| $33.5M | 4.26% |
1,451,267
-96,706
| -6% | -$2.34M |
2013 Q2
4 quarters
|
|
3
PNC Financial Services
PNC
$85.6B
| $30.7M | 3.9% |
344,989
-23,089
| -6% | -$1.97M |
2013 Q2
4 quarters
|
|
4
APA Corp
APA
$16.7B
| $28.2M | 3.59% |
280,633
-22,425
| -7% | -$2.03M |
2013 Q2
4 quarters
|
|
5
MetLife
MET
$63.2B
| $26.8M | 3.41% |
541,362
+10,920
| +2% | +$511K |
2013 Q2
4 quarters
|
|
|
6
Medtronic
MDT
$118B
| $26.3M | 3.34% |
412,222
+102,313
| +33% | +$6.22M |
2013 Q2
4 quarters
|
|
7
Bunge Global
BG
$20.6B
| $24.9M | 3.17% |
329,615
-10,240
| -3% | -$792K |
2013 Q3
3 quarters
|
|
8
Freeport-McMoran
FCX
$100B
| $24.7M | 3.14% |
677,728
-85,050
| -11% | -$2.91M |
2013 Q2
4 quarters
|
|
|
9
Baxter International
BAX
$12.8B
| $24.4M | 3.1% |
621,234
+105,093
| +20% | +$4.2M |
2013 Q4
2 quarters
|
|
|
COV
10
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $23.9M | 3.04% |
265,207
-28,515
| -10% | -$2.13M |
2013 Q3
3 quarters
|
|
11
Microsoft
MSFT
$4T
| $23.5M | 2.99% |
564,657
-29,312
| -5% | -$1.19M |
2013 Q2
4 quarters
|
|
12
Check Point Software Technologies
CHKP
$13.7B
| $21.7M | 2.75% |
323,205
-15,785
| -5% | -$1.04M |
2013 Q3
3 quarters
|
|
13
DELISTED
Walgreens Boots Alliance
WBA
| $18.6M | 2.37% |
251,502
-18,130
| -7% | -$1.27M |
2013 Q2
4 quarters
|
|
|
BHI
14
DELISTED
Baker Hughes
BHI
| $17.7M | 2.25% |
237,772
-59,526
| -20% | -$4.14M |
2013 Q2
4 quarters
|
|
15
Johnson & Johnson
JNJ
$608B
| $17.1M | 2.18% |
163,824
-730
| -0.4% | -$73.8K |
2013 Q2
4 quarters
|
|
16
Avnet
AVT
$7.98B
| $17M | 2.16% |
384,216
-3,132
| -0.8% | -$138K |
2013 Q2
4 quarters
|
|
|
17
Ryder
R
$9.04B
| $16.1M | 2.05% |
182,905
-67,356
| -27% | -$5.64M |
2013 Q2
4 quarters
|
|
18
State Street
STT
$44.1B
| $15.5M | 1.96% |
229,877
-8,998
| -4% | -$592K |
2013 Q2
4 quarters
|
|
19
The Mosaic Company
MOS
$6.07B
| $15M | 1.91% |
303,714
-42,808
| -12% | -$2.11M |
2013 Q2
4 quarters
|
|
|
20
Jabil
JBL
$31.6B
| $14.9M | 1.89% |
711,076
-244,544
| -26% | -$4.55M |
2013 Q2
4 quarters
|
|
21
DELISTED
Diebold Nixdorf Incorporated
DBD
| $14.7M | 1.87% |
365,650
-38,390
| -10% | -$1.47M |
2013 Q2
4 quarters
|
|
22
Tidewater
TDW
$4.23B
| $14.5M | 1.85% |
8,032
-374
| -4% | -$620K |
2013 Q2
4 quarters
|
|
23
DELISTED
Select Medical
SEM
| $14M | 1.78% |
1,669,105
-323,129
| -16% | -$2.51M |
2013 Q3
3 quarters
|
|
24
DELISTED
Tupperware Brands Corporation
TUP
| $13.6M | 1.73% |
162,899
-10,735
| -6% | -$902K |
2013 Q2
4 quarters
|
|
25
Reinsurance Group of America
RGA
$17.1B
| $13M | 1.66% |
165,339
-3,772
| -2% | -$294K |
2013 Q2
4 quarters
|
|
Similar funds
GC
SCP
THC
STCG
BAM
QFA
TOCUITCONY
MAM
Foyston, Gordon, & Payne's Q2 2014 Portfolio in Review
As of Q2 2014, Foyston, Gordon, & Payne held 86 positions worth $787M, down 3% from $812M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Foyston, Gordon, & Payne withdrew a net $58.4M in Q2 2014, closing 5 positions and reducing 49 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
Against the trend, Foyston, Gordon, & Payne opened a new position in Compañía de Cervecerías Unidas worth $693K.
- Foyston, Gordon, & Payne's largest Q2 2014 buy was Compañía de Cervecerías Unidas: 29,600 shares worth $693K.
- Foyston, Gordon, & Payne added most to Teva Pharmaceutical Industries Limited in Q2 2014, an estimated $16M increase.
- Foyston, Gordon, & Payne's biggest Q2 2014 reduction was Ryder, cutting an estimated $5.64M.
- Foyston, Gordon, & Payne fully exited iShares Russell 2000 ETF in Q2 2014, selling an estimated $13.5M.
- Foyston, Gordon, & Payne's ten largest holdings make up 35% of its $787M portfolio in Q2 2014.
- Foyston, Gordon, & Payne opened 1 new position and closed 5 in Q2 2014.
- Foyston, Gordon, & Payne's portfolio value fell 3% quarter-over-quarter to $787M.
Based on Foyston, Gordon, & Payne's 13F filing for Q2 2014, filed 14 Aug 2014.